Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)

• Status: Recruiting
• Trial end date: 2022-09-01

Summary

This study evaluates the effect of aflibercept on the change of cytokines incluing sCD14, MCP-1, IL-6, and ICAM-1 in the aqueous humor of DME patients. Additionally, changes of visual acuity (ETDRS), optical coherence tomography parameters including hyperreflective foci and thickness of macula are also investigated.

• Phase: Phase 4

Details

• Lead Sponsor: Hyewon Chung
• Collaborator: Bayer
• Treatments: Aflibercept